0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Screening for Vascular Complications in Children and Adolescents with Type 1 Diabetes mellitus

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Type 1 diabetes mellitus poses a significant health burden, particularly as a result of its microvascular complications. Clinically evident diabetes-related microvascular complications are extremely rare in childhood and adolescence. However, early functional and structural abnormalities may be present a few years after the onset of the disease. Therefore, regular screening for diabetic microvascular disease, particularly retinopathy and nephropathy, are of foremost importance in paediatric diabetes care. Early detection of diabetic microangiopathy and timely treatment of early signs of these complications have a pivotal role in prevention of blindness and end-stage renal failure in children and adolescents with diabetes.

          Related collections

          Most cited references 2

          • Record: found
          • Abstract: found
          • Article: not found

          Diabetic angiopathy in children.

          Among the secondary complications of diabetes, early stages of retinopathy and nephropathy are of foremost importance in paediatrics. Regular examinations of retinal status and of urinary albumin excretion therefore become necessary with the onset of puberty or after 5 years of diabetes duration. With fluorescein angiography, the first retinal changes can be expected after a median diabetes duration of 9 years, while the median time to clinically relevant background retinopathy is 14 years. This diagnosis is delayed by 4 and 6 years, respectively, if retinopathy is staged exclusively by ophthalmoscopy. Approximately 10 to 20% of children may develop microalbuminuria, starting in early puberty. Several risk factors for the development of diabetic angiopathy have been identified. The degree of glycaemic control, both before and after puberty, appears to be of outstanding importance, but the contribution of other factors may be of varying relevance in the individual patient. These include arterial blood pressure, lipid abnormalities, sex steroids, smoking and genetic factors. Apart from the best possible metabolic regulation, early treatment with antihypertensive drugs has been shown to be beneficial in hypertensive adolescents but may also be renoprotective in normotensive adolescents with permanent microalbuminuria. However, the relatively high prevalence of intermittent and transient microalbuminuria in paediatric patients (2 and 3% respectively), with unknown prognostic relevance, complicate the decision to start such treatment for a lifetime. Nevertheless, the early detection of risk factors and the implementation of appropriate intervention strategies are necessary to improve the long-term prognosis for children with diabetes.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Progression of borderline increases in albuminuria in adolescents with insulin-dependent diabetes mellitus.

            We aimed to determine the natural history of borderline increases in albuminuria in adolescents with insulin-dependent (Type 1) diabetes mellitus (IDDM) and factors which are associated with progression to persistent microalbuminura. Fifty-five normotensive adolescents with IDDM and intermittent microalbuminura (overnight albumin excretion ratte of 20-200 micrograms min-1 on one of three consecutive timed collections, n = 29) or borderline albuminura (mean overnight albumin excretion rate of 7.2-20 micrograms min-1 on one of three consecutive timed collections, n = 30) were followed prospectively at 3 monthly intervals. The endpoint was persistent microalbuminuria defined as a minimum of three of four consecutive overnight albumin excretion rates of greater than 20 micrograms min-1. One hundred and forty-two adolescents with IDDM and normoalbuminura were also followed prospectively. Fifteen of the 59 patients (25.4%) with intermittent (9/29) or borderline (6/30) albuminura progressed to persistent microalbuminura (progressors) over 28 (15-50) months [median (range)] in comparison with two of the 142 patients with normoalbuminuria at entry (relative risk = 12.6; p = 0.001). Progressors to persistent microalbuminura were pubertal and had higher systolic (p = 0.02) and diastolic (p = 0.02) blood pressure, and HbA1c (p = 0.004) than non-progressors. All patients remained normotensive. Glomerular filtration rate, apolipoproteins, dietary phosphorus, protein and sodium intakes, and prevalence of smoking did not differ between progressors and non-progressors. Total renin was higher in the diabetic patients without a difference between progressors and non-progressors. In conclusion there is a relatively high rate of progression to persistent microalbuminuria in pubertal adolescents with borderline increases in albuminura and duration greater than 3 years. These patients require attention to minimize associated factors of poor metabolic control and higher blood pressure in the development of incipient nephropathy.
              Bookmark

              Author and article information

              Journal
              HRE
              Horm Res Paediatr
              10.1159/issn.1663-2818
              Hormone Research in Paediatrics
              S. Karger AG
              978-3-8055-7415-0
              978-3-318-00844-9
              1663-2818
              1663-2826
              2002
              2002
              17 November 2004
              : 57
              : Suppl 1
              : 113-116
              Affiliations
              Department of Pediatrics, University of Chieti, Italy
              Article
              53329 Horm Res 2002;57(suppl 1):113–116
              10.1159/000053329
              11979039
              © 2002 S. Karger AG, Basel

              Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

              Page count
              Tables: 1, References: 12, Pages: 4
              Categories
              Meet-the-Expert Session

              Comments

              Comment on this article